Acute myeloid leukemia (AML), the most prevalent acute leukemia in adults, is an
aggressive hematological malignancy arising in hematopoietic stem and progenitor cells …

Opinion statement Acute myeloid leukemia (AML) disease prognosis is poor and there is a
high risk of chemo-resistant relapse for both young and old patients. Thus, there is a …

Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically
heterogeneous disease, and its incidence is increasing as the population ages …

In recent years, research in genomics has resulted in the rapid uncovering of the molecular
pathogenesis of acute myeloid leukemia (AML). The identification of the genetic …

Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that
accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric …

Acute myeloid leukaemia (AML) is a haematopoietic stem cell disorder, that is characterized
by the clonal expansion of myeloid blasts and suppression of normal haematopoiesis. The …

The effective treatment of acute myeloid leukemia (AML) is very challenging. Due to the
immense heterogeneity of this disease, treating it using a “one size fits all” approach is …

Acute myeloid leukemia (AML) is a heterogeneous hematopoietic neoplasm which results in
clonal proliferation of abnormally differentiated hematopoietic cells. In this review …

A fundamental difficulty in testing “targeted therapies” in acute myeloid leukemia (AML) is
the limitations of preclinical models in capturing inter-and intrapatient genomic …

Chromosomal rearrangements of the mixed lineage leukemia (MLL/KMT2A) gene leading to
oncogenic MLL-fusion proteins occur in~ 10% of acute leukemias and are associated with …